3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pain
5
Neoplasms
2
Multiple Myeloma
2
Cancer Pain
2
Squamous Cell Carcinoma of Head and Neck
1
Pain, Postoperative
1
Paget Disease, Extramammary
1
Ovarian Neoplasms
1
Lymphoma
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Agnosia
1
Interventions
Carboplatin
190
Cisplatin
156
Pemetrexed
151
Paclitaxel
127
Docetaxel
109
pembrolizumab
87
Gemcitabine
73
Erlotinib Hydrochloride
44
Radiotherapy
39
Vinorelbine
35
Gefitinib
34
durvalumab
31
Bevacizumab
28
Nivolumab
26
Drug Therapy
23
atezolizumab
22
osimertinib
19
130-nm albumin-bound paclitaxel
19
tislelizumab
16
Crizotinib
16
Radiosurgery
15
Etoposide
14
Surgical Procedures, Operative
11
Afatinib
11
Ipilimumab
10
icotinib
9
aumolertinib
9
Albumin-Bound Paclitaxel
9
Specimen Handling
8
Observation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Non-Small-Cell Lung
×
Acetaminophen
×
Clear all
NCT06305754
2026-05-29
MK-2870-009
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
520 enrolled